Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson medTech Segment Total — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2025
33,792
Period ended Dec 28, 2025
Change on a year earlier
+6.1%
31,857 in FY2024
History
11 years
Since FY2015
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | MedTech Segment Total — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 33,792 | +6.1% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 31,857 | +4.8% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 30,400 | +10.8% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 27,427 | +1.4% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 27,060 | +17.9% | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 22,959 | -11.6% | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 25,963 | -3.8% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 26,994 | +1.5% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 26,592 | +5.9% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 25,119 | -0.1% | Form 10-K (filed 2019-02-20) ↗ |
| FY2015 | Jan 3, 2016 | 25,137 | – | Form 10-K (filed 2018-02-21) ↗ |
Breakdown
What makes up medtech segment total — worldwide sales ($m)
- MedTech Segment Total — U.S. sales ($M)17,408 · FY2025
- MedTech Segment Total — International sales ($M)16,384 · FY2025
- MedTech Segment Total — Worldwide reported growth YoY (%)6.1% · FY2025
- MedTech Segment Total — Worldwide operational (constant-currency) growth YoY (%)5.4% · FY2025
- MedTech — Worldwide adjusted operational growth ex-A&D YoY (%)4.3% · FY2025
- Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide sales ($M)8,928 · FY2025
- Surgery Franchise — Worldwide sales ($M)10,137 · FY2025
- Orthopaedics Franchise — Worldwide sales ($M)9,258 · FY2025
- Vision Franchise — Worldwide sales ($M)5,468 · FY2025
- Diabetes Care Franchise [divested FY2018–FY2019] — Worldwide sales ($M)0 · FY2019
- Diagnostics Franchise [divested through FY2018] — Worldwide sales ($M)0 · FY2019
Cite this data
StockData. (2026). Johnson & Johnson MedTech Segment Total — Worldwide sales ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg_medtech
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.